Lucid Diagnostics (NASDAQ:LUCD) Trading Down 0.5% – Here’s What Happened

Lucid Diagnostics Inc. (NASDAQ:LUCD)’s share price dropped 0.5% on Monday . The company traded as low as $0.83 and last traded at $0.84. Approximately 111,094 shares were traded during mid-day trading, a decline of 67% from the average daily volume of 333,416 shares. The stock had previously closed at $0.85.

Analyst Ratings Changes

Several research firms have recently issued reports on LUCD. Ascendiant Capital Markets dropped their price objective on shares of Lucid Diagnostics from $7.25 to $7.00 and set a “buy” rating on the stock in a report on Monday, December 9th. Needham & Company LLC restated a “buy” rating and set a $2.50 price target on shares of Lucid Diagnostics in a research note on Thursday, November 14th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $3.00 price target on shares of Lucid Diagnostics in a report on Thursday, November 14th. Finally, Cantor Fitzgerald decreased their price objective on Lucid Diagnostics from $3.00 to $2.00 and set an “overweight” rating on the stock in a report on Friday, November 15th. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $3.63.

Lucid Diagnostics Stock Performance

The firm has a 50 day moving average price of $0.87 and a two-hundred day moving average price of $0.85. The company has a market capitalization of $48.94 million, a P/E ratio of -0.72 and a beta of 1.45.

About Lucid Diagnostics

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.